bioRxivPharmacology & Toxicology
Discovery of New Broad-Spectrum Anti-Infectives for Eukaryotic Pathogens Using Bioorganometallic Chemistry
Y. Lin, H. Jung, C. A. Bulman, J. Ng, R. Vinck, C. O'Beirne, M. S. Moser, N. Tricoche, R. Peguero, R. W. Li, J. F. Urban, P. Le Pape, F. Pagniez, M. Moretto, T. Weil, S. Lustigman, K. Cariou, M. Mitreva, J. Sakanari, G. Gasser
Abstract
Drug resistance observed with many anti-infectives clearly highlights the need for new broad-spectrum agents to treat especially neglected tropical diseases (NTDs) caused by eukaryotic parasitic pathogens including fungal infections. Since these diseases target the most vulnerable communities who are disadvantaged by health and socio-economic factors, new agents should be, if possible, easy-to-prepare to allow for commercialization based on their low cost. In this study, we show that simple modification of one of the most well-known antifungal drugs, fluconazole, with organometallic moieties not only improves the activity of the parent drug but also broadens the scope of application of the new derivatives. These compounds were highly effective in vivo against pathogenic fungal infections and potent against parasitic worms such as Brugia, which causes lymphatic filariasis and Trichuris, one of the soil-transmitted helminths that infects millions of people globally. Notably, the identified molecular targets indicate a mechanism of action that differs greatly from the parental antifungal drug, including targets involved in biosynthetic pathways that are absent in humans, offering great potential to expand our armamentarium against drug-resistant fungal infections and NTDs targeted for elimination by 2030. Overall, the discovery of these new compounds with broad-spectrum activity opens new avenues for the development of treatments for several current human infections, either caused by fungi or by parasites, including other NTDs, as well as newly emerging diseases. ONE-SENTENCE SUMMARYSimple derivatives of the well-known antifungal drug fluconazole were found to be highly effective in vivo against fungal infections, and also potent against the parasitic nematode Brugia, which causes lymphatic filariasis and against Trichuris, one of the soil-transmitted helminths that infects millions of people globally.
- organism: human
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Target-based discovery of a broad spectrum flukicide
D. J. Sprague, S.-K. Park, … J. Marchant·bioRxiv·Sep 22, 2023
- synergistic and antagonistic drug interactions in the treatment of systemic fungal infections
M. A. Wambaugh, S. T. Denham, … J. C. S. Brown·bioRxiv·Nov 15, 2019
- Antifungal activity of 2,3-diphenyl-2,3-dihydro-1,3-thiaza-4-ones against two human pathogenic fungi
L. C. Liporagi Lopes, H. F. Sobhi, … A. Casadevall·bioRxiv·Jun 27, 2020
- A Nickel N-Heterocyclic Biscarbene Complex Derived from Caffeine Enhances Fluconazole Efficacy against Candida glabrata
Cláudia Malta-Luís, Giulia Romeo, … Catarina Pimentel·bioRxiv·Mar 3, 2026
- Discovery and Repurposing of Pharmaceutical Agents as Antifungals: In vivo activity against Coccidioides
H. Mead, M. Valentine, … B. M. Barker·bioRxiv·Feb 21, 2024
- Characterization of a selective, iron-chelating antifungal compound that disrupts fungal metabolism and synergizes with fluconazole
J. Corrales, L. Ramos-Alonso, … J. Enserink·bioRxiv·Aug 9, 2023